中高危前列腺癌患者基线68Ga-PSMA-11正电子发射断层扫描/计算机断层扫描淋巴结状态对治疗失败具有预后价值:proPSMA试验随访
proPSMA研究预设分析旨在评估68Ga-PSMA-11 PET-CT所示区域淋巴结受累的预后价值。302例中高危前列腺癌患者随机分组,251例无远处转移者纳入分析,中位随访至54个月。PSMA PET-CT定义的miN1M0组治疗失败风险高于miN0M0组(HR 2.1,95%CI 1.2-3.7,p=0.01),而CT/骨扫描定义的N分期无预后价值(HR 0.6,95%CI 0.1-2.4,p=0.45)。
要点
- PSMA PET-CT检出区域淋巴结转移(miN1M0)者治疗失败风险高于miN0M0者(HR 2.1,p=0.01)。
- CT/骨扫描定义的N1M0与N0M0间治疗失败无显著差异(HR 0.6,p=0.45)。
- 多因素校正PSA、Gleason分级组和年龄后,PSMA PET-CT miN1M0仍具预后价值(HR 2.0,p=0.007)。
核心结论
- 基线PSMA PET-CT区域淋巴结分期对中期肿瘤学结局具有预后价值,可识别治疗失败风险较高的患者。
研究设计与样本
- proPSMA研究预设分析,中高危前列腺癌患者随机接受68Ga-PSMA-11 PET-CT或CT加骨扫描作为一线或二线影像。
- 共302例患者在10个中心随机分组,其中294例接受PSMA PET-CT,251例无远处转移(miM0)者纳入本分析。
- 患者接受根治性手术或放疗±雄激素剥夺治疗,随访至54个月。
主要发现
- PSMA PET-CT miN0M0组无治疗失败生存(FFTF)优于miN1M0组(HR 2.1,95%CI 1.2-3.7,p=0.01)。
- CT/骨扫描定义的N0M0与N1M0间FFTF无显著差异(HR 0.6,95%CI 0.1-2.4,p=0.45)。
- 多因素分析校正PSA、Gleason分级组和年龄后,PSMA PET-CT miN1M0 vs miN0M0仍具预后价值(HR 2.0,95%CI 1.10-3.64,p=0.007)。
关键数值与推荐
- 治疗失败定义为生化失败、开始挽救治疗或出现远处转移。
- 中高危定义:Gleason分级组3-5、PSA≥20 ng/ml或临床分期≥T3。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: There is uncertainty regarding the clinical significance of 68Ga-PSMA-11 positron emission tomography (PET) computed tomography (CT) findings in men with prostate cancer. In this prespecified objective of the proPSMA study, we report the prognostic value of PET-defined nodal involvement. METHODS: Men with intermediate- to high-risk prostate cancer (grade group 3-5, prostate-specific antigen [PSA] ≥20 ng/ml, or clinical stage ≥T3) underwent 68Ga-PSMA-11 PET-CT or CT and bone scanning as first- or second-line imaging. Patients without distant metastatic disease (miM0) in either arm were stratified by prostate-specific membrane antigen (PSMA) PET-CT negative (miN0) or positive (miN1) regional nodal status and followed for up to 54 mo. Treatment failure was defined as biochemical failure, commencement of salvage therapy, or development of distant metastatic disease. Freedom from treatment failure (FFTF) was plotted on Kaplan-Meier curves for patients with miN0 and miN1 cancer based on PET-CT and CT/bone scan classification. Cox proportional hazards were used to derive a hazard ratio (HR) for FFTF. KEY FINDINGS AND LIMITATIONS: A total of 302 patients were randomised at ten sites. Of them, 294 underwent a PSMA PET-CT. In all, 251 patients with miM0 disease were included in this analysis. Patients were treated with curative-intent surgery or radiotherapy ± androgen deprivation. FFTF was greater in the PSMA PET-CT miN0M0 group than in the miN1M0 group (HR 2.1 [95% confidence interval {CI} 1.2-3.7], p = 0.01). CT/bone scan-defined N0M0 versus N1M0 was not prognostic for FFTF (HR 0.6, 95% CI 0.1-2.4, p = 0.45). In a multivariate analysis, PSMA PET-CT miN1M0 versus miN0M0 remained prognostic after adjusting for PSA, Gleason grade group, and age (HR 2.0, 95% CI 1.10-3.64, p = 0.007). CONCLUSIONS AND CLINICAL IMPLICATIONS: PSMA PET-CT regional nodal staging at baseline is prognostic for medium-term oncological outcomes, identifying patients at a higher risk of treatment failure. PATIENT SUMMARY: Men with prostate cancer who have cancer in their nearby lymph nodes observed on a prostate-specific membrane antigen positron emission tomography scan have poorer outcomes than men who have no nearby lymph node involvement.
引用
- Hofman MS, Kasivisvanathan V, Link E, et al. Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial. Eur Urol Oncol. 2024. PMID: 39613566. doi:10.1016/j.euo.2024.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。